A WHO-UNICEF joint statement encouraging greater health commodity supply chain integration for temperature-sensitive pharmaceuticals where appropriate, 19 November 2020
Oxfam’s report found that Covid-19 has the potential to increase economic inequality in almost every country at once, the first time this has happened since records began over a century ago. It sets out how a rigged economy is enabling a super-rich elite to amass wealth in the middle of the worst ...recession since the Great Depression, while billions of people are struggling amid the worst job crisis in over 90 years. Unless rising inequality is tackled, half a billion more people could be living in poverty on less than $5.50 (£4.00) a day in 2030, than at the start of the pandemic.
more
A guide on how to prevent and address social stigma surrounding coronavirus disease (COVID-19) for Government, media and local organisations working on the disease.
Available in different languages: Arabic, English, French, Indonesia, Hindi, Korean, Japanese, Thai, Vientmese, Bengali, Malay, Portu...guese, Spanish, Tamil, Chinese
more
This curriculum will help you, and your community, understand the science of the virus that causes COVID-19 and other viruses like it. It will help you to figure out how this virus is impacting or affecting you or may impact you in the future. It will help you to understand the actions that you can ...take to keep yourself and your community safe.
It is available in 15 languages. Download for free at the website
more
Coronaviruses are a large family of viruses that are known to cause illness ranging from the common cold to more severe diseases such as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS).
A novel coronavirus (CoV) was identified in 2019 in Wuhan, China. This is a ...new coronavirus that has not been previously identified in humans.
This course provides a general introduction to nCoV and emerging respiratory viruses and is intended for public health professionals, incident managers and personnel working for the United Nations, international organizations and NGOs.
This course is also available in the following languages:
français - Español - 中文 - Português - العربية - русский - Türkçe - српски језик - فارسی - हिन्दी, हिंदी - македонски јазик - Tiếng Việt - Indian sign language - magyar - Bahasa Indonesia - বাংলা - اردو - Kiswahili - አማርኛ - ଓଡିଆ - Hausa - Tetun - Deutsch - Èdè Yorùbá - Asụsụ Igbo - ਪੰਜਾਬੀ - isiZulu
more
Les retours d’information de la communauté présentés dans le présent rapport ont été recueillis par le biais des personnes chargées de l’engagement communautaire et de la redevabilité (CEA) dans 10pays africains, et grâce à la collecte de données primaires.Il a été demandé aux pers...onnes chargées du CEA de la Société nationale de la Croix-Rouge et du Croissant-Rouge de partager les principales rumeurs, observations, croyances, questions ou suggestions qu’ils entendent dans leur pays et de les classer par ordre de fréquence. Les chargés de mission du CEA ont fourni des informations de cette manière aux pays suivants: Afrique du Sud, Botswana, Burundi, Cameroun, Niger.
more
After 100 years of chemotherapy with impractical and toxic drugs, an oral cure for human African trypanosomiasis (HAT) is available: Fexinidazole. In this case, we review the history of drug discovery for HAT with special emphasis on the discovery, pre-clinical development, and operational challenge...s of the clinical trials of fexinidazole. The screening of the Drugs for Neglected Diseases initiative (DNDi) HAT-library by the Swiss TPH had singled out fexinidazole, originally developed by Hoechst (now Sanofi), as the most promising of a series of over 800 nitroimidazoles and related molecules. In cell culture, fexinidazole has an IC50 of around 1 µM against Trypanosoma brucei and is more than 100-fold less toxic to mammalian cells. In the mouse model, fexinidazole cures both the first, haemolymphatic, and the second, meningoencephalitic stage of the infection, the latter at 100 mg/kg twice daily for 5 days. In patients, the clinical trials managed by DNDi and supported by Swiss TPH mainly conducted in the Democratic Republic of the Congo demonstrated that oral fexinidazole is safe and effective for use against first- and early second-stage sleeping sickness. Based on the positive opinion issued by the European Medicines Agency in 2018, the WHO has released new interim guidelines for the treatment of HAT including fexinidazole as the new therapy for first-stage and non-severe second-stage sleeping sickness caused by Trypanosoma brucei gambiense (gHAT). This greatly facilitates the diagnosis and treatment algorithm for gHAT, increasing the attainable coverage and paving the way towards the envisaged goal of zero transmission by 2030.
more
Part 3: Use Safe Burial Practices